Researchers at the Johnson Family Equine Hospital to study superficial radiation therapy in horses following the University’s successful use in companion animals
BOCA RATON, Fla., July 20, 2022 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the expansion of its relationship with Colorado State University (CSU) College of Veterinary Medicine and Biomedical Studies with the acquisition of a second SRT-100™ system by CSU. Studies at CSU’s new Johnson Family Equine Hospital in Fort Collins are expected to be conducted primarily in ophthalmic indications.
Previously, CSU researchers treated a bulldog and a matamata turtle with an SRT-100 system at the Flint Animal Cancer Center at the Colorado State James L. Voss Veterinary Teaching Hospital.
“We are excited to continue our relationship with Sensus Healthcare and look forward to expanding our work to include horses,” said Kathryn L. Wotman, DVM, DACVIM (Large Animal), DACVO, Assistant Professor, Comparative Ophthalmology, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Johnson Family Equine Hospital. “CSU researchers have generated compelling results with SRT in a variety of tumor types and we believe the technology warrants further study. Receipt of an SRT system dedicated to our new equine facility supports our commitment to improve animal health. We hope to publish data on the treatment of horses next year.”
Commenting on the agreement, John Heinrich, Ph.D., member of the Sensus Healthcare board of directors and the key relationship contact with CSU, added, “We are delighted to expand our relationship with the Colorado State School of Veterinary Medicine with a second SRT system. The recent dedication of the Johnson Family Equine Hospital provides an ideal environment for the cooperative implementation and validation of equine oncological applications of our technology.”
Sensus notes that should the research from CSU continue to show beneficial clinical outcomes, veterinary medicine could be an important new market for its superficial radiation therapy systems, with approximately 30,000 veterinary practices in the U.S.
About the Johnson Family Equine Hospital
Colorado State University initiated its new, state-of-the-art equine hospital in November 2021. The hospital provides more than 25 equine clinicians to care for up to 4,000 equine patients annually. Additionally, veterinary students (approximately 550 at a time) in the CSU Doctor of Veterinary Medicine Program will benefit from the facility and its many up-to-date research and treatment methods.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from our international operations; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
